Goodnick P J, Goldstein B J
Department of Psychiatry and Behavioral Sciences, Health Services Research Center, University of Miami School of Medicine, Florida 33136, USA.
J Psychopharmacol. 1998;12(3 Suppl B):S21-54. doi: 10.1177/0269881198012003031.
Since their introduction, the selective serotonin reuptake inhibitors (SSRIs) have become one of the most widely used classes of medication in psychiatry. Their popularity is based on apparent efficacy over a wide range of disorders and a favorable side-effect profile. However, as with any psychotropic medication, considerable data are required to define where a drug works and where it does not. There is now a wealth of evidence demonstrating that SSRIs may differ in their efficacy profiles in certain depressive symptoms, in different subtypes of depression, with respect to their ability to maintain efficacy over time, on broader outcomes such as quality of life, and in the consistency of the usually effective minimum therapeutic dose across the age spectrum and across indications. Although this review includes data on all SSRIs, it focuses on fluoxetine and sertraline, which in addition to being the most widely used SSRIs are also the most widely studied. The relative quantity and quality of data on these two SSRIs means that it is possible to make relatively firm inferences regarding their differential effects on affective symptoms and quality of life.
自选择性5-羟色胺再摄取抑制剂（SSRIs）问世以来，它们已成为精神病学领域应用最为广泛的药物类别之一。其广泛应用基于对多种病症具有明显疗效以及良好的副作用特征。然而，与任何精神药物一样，需要大量数据来界定一种药物的有效范围和无效范围。现在有大量证据表明，SSRIs在某些抑郁症状、不同抑郁亚型、维持疗效的能力、对诸如生活质量等更广泛结局的影响，以及在不同年龄范围和适应症中通常有效的最小治疗剂量的一致性方面，其疗效可能存在差异。尽管本综述涵盖了所有SSRIs的数据，但重点关注氟西汀和舍曲林，这两种药物不仅是使用最广泛的SSRIs，也是研究最广泛的。这两种SSRIs相关数据的数量和质量，意味着有可能就它们对情感症状和生活质量的不同影响做出相对确凿的推断。
